1、January 8,2024J.P.Morgan Presentation Highly ConfidentialForward looking statements and non-GAAP financial information 2This presentation(as well as the oral statements made with respect to information contained in this presentation)contains statements about Bristol-Myers Squibb Companys(the“Company

2、”)future financial results,plans,business development strategy,anticipated clinical trials,results and regulatory approvals that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995.All statements that are not sta

3、tements of historical facts are,or may be deemed to be,forward-looking statements.Actual results may differ materially from those expressed in,or implied by,these statements as a result of various factors,including,but not limited to,(i)new laws and regulations,(ii)our ability to obtain,protect and

4、maintain market exclusivity rights and enforce patents and other intellectual property rights,(iii)our ability to achieve expected clinical,regulatory and contractual milestones on expected timelines or at all,(iv)difficulties or delays in the development and commercialization of new products,(v)dif

5、ficulties or delays in our clinical trials and the manufacturing,distribution and sale of our products,(vi)adverse outcomes in legal or regulatory proceedings,(vii)risks relating to acquisitions,divestitures,alliances,joint ventures and other portfolio actions and(viii)political and financial instab

6、ility,including changes in general economic conditions.These and other important factors are discussed in the Companys most recent annual report on Form 10-K and quarterly reports on Form 10-Q and current reports on Form 8-K.These documents are available on the U.S.Securities and Exchange Commission

7、s website,on the Companys website or from Bristol-Myers Squibb Investor Relations.No forward-looking statements can be guaranteed.In addition,any forward-looking statements and clinical data included herein are presented only as of the date hereof.Except as otherwise required by applicable law,the C

8、ompany undertakes no obligation to publicly update any of the provided information,whether as a result of new information,future events,changed circumstances or otherwise.This presentation does not constitute a solicitation of a proxy,an offer to purchase or a solicitation of an offer to sell any se

9、curities.This presentation includes certain non-Generally Accepted Accounting Principles(“GAAP”)financial measures that we use to describe the Companys performance.The non-GAAP financial measures are provided as supplemental information and are presented because management has evaluated the Companys

10、 financial results both including and excluding the adjusted items or the effects of foreign currency translation,as applicable,and believes that the non-GAAP financial measures presented portray the results of the Companys baseline performance,supplement or enhance managements,analysts and investor

11、s overall understanding of the Companys underlying financial performance and trends and facilitate comparisons among current,past and future periods.This presentation also provides certain revenues and expenses or other financial measures excluding the impact of foreign exchange(“Ex-FX”).We calculat

12、e foreign exchange impacts by converting our current-period local currency financial results using the prior period average currency rates and comparing these adjusted amounts to our current-period results.Ex-FX financial measures are not accounted for according to GAAP because they remove the effec

13、ts of currency movements from GAAP results.The non-GAAP information presented herein provides investors with additional useful information but should not be considered in isolation or as substitutes for the related GAAP measures.Moreover,other companies may define non-GAAP measures differently,which

14、 limits the usefulness of these measures for comparisons with such other companies.We encourage investors to review our financial statements and publicly filed reports in their entirety and not to rely on any single financial measure.An explanation of these non-GAAP financial measures and a reconcil

15、iation to the most directly comparable financial measure are provided with this presentation and available on our website at note that a reconciliation of forward-looking non-GAAP gross margin,non-GAAP operating margin,non-GAAP operating expenses and non-GAAP tax rate is not provided because a compa

16、rable GAAP measure for such measures are not reasonably accessible or reliable due to the inherent difficulty in forecasting and quantifying measures that would be necessary for such reconciliation.Namely,we are not,without unreasonable effort,able to reliably predict the impact of the unwind of inv

17、entory purchase price adjustments,accelerated depreciation and impairment of property,plant and equipment and intangible assets,and stock compensation resulting from acquisition-related equity awards,or currency exchange rates.In addition,the Company believes such a reconciliation would imply a degr

18、ee of precision and certainty that could be confusing to investors.These items are uncertain,depend on various factors and may have a material impact on our future GAAP results.Highly ConfidentialWe are writing the next chapter in our history3Our overarching goal is to achieve sustainable,top-tier g

19、rowth by the end of the decadeBMS has entered another period of renewal in its long history of scientific achievements and delivering innovative medicines to patientsWe have a Growth Portfolio positioned to generate a more diverse company over the decade,with strong cash flow from legacy brands to i

20、nvestWe are focused on maximizing performance through 2025 and navigating our transition period in the middle of the decadeHighly ConfidentialWe will navigate a dynamic environment4 4Evolution of the global regulatory and access environment(e.g.,IRA)Loss of exclusivity for multiple major productsInc

21、reasingly intense competitive environmentIndustry HeadwindsHighly ConfidentialOur overarching goal is to achieve sustainable,top-tier growthTransition periodMaximize performance through 2025Sustainable,top-tier growth from late 2020s5Revenue,illustrativeHighly ConfidentialBMS enters this period with

22、 a number of key strengths6Robust&innovative pipelineDifferentiated platforms with significant potentialFinancial strength&flexibility Growing position in large,attractive TAsProfitable business with meaningful cash generationStrong balance sheet with flexibility to invest Continued commitment to re

23、turn cash to shareholdersCenter of the innovative cell therapy ecosystemIndustry-leadingcapabilities in targeted protein degradationDifferentiated actinium-based radiopharmaceutical platform1Expanding registrational pipeline,growing from 6 to 12assetsRobust early-stage pipeline with 30+assets and op

24、portunity to deliver 10 INDs per yearLeadership positions in Oncology,Hematology&CardiovascularGrowing presence in Immunology&NeuroscienceRecently launched assets with significant growth potential1.Subject to satisfaction of customary closing conditions;anticipated closing of RayzeBio in 1H 2024 Hig

25、hly Confidential11major brands across 4TAs+12assets in/entering registrational stage+30+assets in early-stage clinical development+Assets from ongoing BDLegacy PortfolioGrowth PortfolioWe have a valuable Growth Portfolio7Generating strong cash flow andflexibility to invest in growthIncluding a more

26、diversified and robust range of products$25B sales(2023)CardiovascularOncologyHematologyImmunology1Legacy:Small Molecule Post-LoE products or products with 3 years to potential impact from major LoE or IRA;Growth:3 years until major LoE event or potential IRA impact.“Major”brands include those with$

27、1Bn+risk-adjusted consensus annual sales;Only logos for major brands are shown1.Subject to satisfaction of customary closing conditions;anticipated closing of Mirati by 1H 2024;2.Partnered with 2SeventyBio2NOT FOR PRODUCT PROMOTIONAL USEHighly ConfidentialFocus on disciplined executionHow we will de

28、liver81.Build on our leadership in Oncology,Hematology&Cardiovascular2.Continue to grow our presence in Immunology&Neuroscience4.Strategic capitalallocation3.Maximize valuefrom our differentiated pipeline&platformsHighly ConfidentialFocus on disciplined executionHow we will deliver91.Build on our le

29、adership in Oncology,Hematology&Cardiovascular2.Continue to grow our presence in Immunology&Neuroscience4.Strategic capital allocation3.Maximize valuefrom our differentiated pipeline&platformsHighly ConfidentialOncology:Our strategy to build on our leadership10Not exhaustive of assets,programs,or in

30、dications1.U.S.Regulatory path opens up indications with Q2W and Q4W;2.Subject to satisfaction of customary closing conditions;anticipated closing of Mirati,SystImmune,and RayzeBio in 1H 2024Extend durability in IOExpand into targeted therapiesDeepen platform capabilitiesCell TherapyADC22Radiopharma

31、ceutical therapyTargeted protein degradation15+additional oncology assets in Ph 1/22subcutaneous nivolumab1AR LDDExploring in solid tumorsNOT FOR PRODUCT PROMOTIONAL USEHighly ConfidentialSubcutaneous nivolumab&Opdualag:Extending durability of our IO business11MelanomaLungGI/OtherOther2022MelanomaLu

32、ngRenalGI/Other2028$8BRevenue,not to scalePotential to address 65-75%of Opdivo U.S.indications2Opportunity to further extend with IO pipelineRenalsubcutaneous nivolumab11.U.S.Regulatory path opens indications with Q2W and Q4W;2.Assume extrapolation to non-Yervoy combinations and converting at least

33、half of addressable populationNOT FOR PRODUCT PROMOTIONAL USEHighly ConfidentialHematology:Strengthening our position across a broad array of conditions125+additional hematology assets in Ph 1/2Extend leadership in multiple myelomaTransform outcomes inleukemia/lymphomaExpand impact in non-malignant

34、hemeExpansion opportunities across 1L TD MF,1L NTD MDS,and alpha-thalassemia2Best-in-class CAR T approved with the broadest label in LBCLNot exhaustive of assets,programs,or indications;1.Developed in partnership with 2SeventyBio;2.Ex-US studyComplex biologicsTargeted protein degradationiberdomideme

35、zigdomidealnuctamabCell TherapyGPRC5DGPRC5D x BCMAgolcadomideTargeted protein degradationADCGSPT1 degraderNOT FOR PRODUCT PROMOTIONAL USE1Highly ConfidentialSignificant increase in manufacturing capacity planned this yearBreyanzi:Best-in-class CAR T across the broadest array of B-cell malignancies13

36、LBCLCLL/SLLFL/MCLPotential Patient BasePatient population size,not to scaleBroadest label in 2L+LBCL4x+increase inmedian EFSFirst&only registrational data for CLL/SLLFDA Priority Review PDUFA:March 2024Potential best-in-disease(R/R FL)96%complete responseApprovedRegistrationalPhase I or IILBCL:Large

37、 B-Cell Lymphoma;CLL:Chronic Lymphocytic Leukemia,SLL:Small Lymphocytic Lymphoma;FL:Follicular Lymphoma,MCL:Mantle Cell Lymphoma;1.Assumes regulatory approval for CLL/SLL,FL,&MCL 2xexpansion1No other CD19 CAR T approvedNOT FOR PRODUCT PROMOTIONAL USEHighly ConfidentialReblozyl:Significant growth opp

38、ortunities in MDS-associated anemia and beyondOngoing registrational studies1L TD myelofibrosis(INDEPENDENCE)20251L NTD MDS (ELEMENT)2027Exploratory/PoC studiesAlpha-thalassemia2 2025New standard of care in 1L MDS-associated anemia1L approval increases market opportunity by 4xOpportunity to further

39、expand12023 U.S.patient estimates2L+RS+MDS1L MDS2K8KFirst and only therapy to demonstrate head-to-head superiority over epoetin alphaApproved in the U.S.with a broad label in lower-risk MDS-associated anemiaGlobal filings underway141.Years indicate expected data readouts;2.Ex-US studyNOT FOR PRODUCT

40、 PROMOTIONAL USEHighly ConfidentialCardiovascular:Opportunity for sustained leadership with impact for millions of patients15Not exhaustive of assets,programs,or indications 1.Developed in partnership with J&J Innovative MedicinesGrowing opportunity in cardiomyopathies and heart failureExtending suc

41、cessful history in thrombosisMYK-224milvexian1Expansion opportunities in CV diseases with Avidity Biosciences collaborationNOT FOR PRODUCT PROMOTIONAL USEHighly ConfidentialPotential expansion in symptomatic nHCM(ODYSSEY-HCM):Phase 3 trial underway to expand the market;data expected in 2025Camzyos:F

42、irst and only myosin inhibitor approved in oHCMQ1Q2Q3Q4Q5Q6CamzyosEntrestoStrong launch momentumSignificant untapped potential within oHCMLevers to deliverTime post-launch,quarters1.Mizuho Research(Dec 2023)2.Entresto&Camzyos are approved for two different types of cardiac patients 3.BMS

43、Internal Analysis Maximize strong clinical profile Expand prescriber base and further penetrate NYHA Class II Improve patient awareness through DTC(including QoL impact)Increase diagnosis through AIQuarterly U.S.sales,$M1,275K Prevalent,diagnosed,symptomatic oHCM patients in the U.S.&similar prevale

44、nce in Top 5 EU3NOT FOR PRODUCT PROMOTIONAL USEHighly ConfidentialMilvexian1,2:Opportunity to expand anticoagulation beyond FXa to benefit millions of patients17Anti-platelets4,5 SSP ACSFactor Xa AF4milvexian7.5M patients3in U.S.with thrombotic diseases need treatmentPotential differentiated profile

45、 for SSP,ACS,AF Ph3 studies in Secondary Stroke Prevention(SSP),Acute Coronary Syndrome(ACS)&Atrial Fibrillation(AF)Confidence in AF Ph3 supported by:Ph2 study in TKR evaluating 16-fold dose range 100mg BID dose exhibiting comparable efficacy to historical FXa Differentiated dose response for bleedi

46、ng Potential to be the only Oral FXIa in AF1.U.S.FDA granted Fast Track Designation to all 3 indications 2.Developed in partnership with J&J Innovative Medicines 3.Decision Resource Group,BMS Internal Analysis 4.Current standard of care for indication(s)5.FXa not used due to risk of bleedingNOT FOR

47、PRODUCT PROMOTIONAL USEHighly ConfidentialFocus on disciplined executionHow we will deliver181.Build on our leadership in Oncology,Hematology&Cardiovascular2.Continue to grow our presence in Immunology&Neuroscience4.Strategic capital allocation3.Maximize valuefrom our differentiated pipeline&platfor

48、msHighly ConfidentialEstablishing a growing presence in Immunology19Addressing diverse immunologic diseases with high unmet need impacting 8M+1patientsMaximize existing core indicationsExpand indication opportunities of leading marketed productsLaunch next wave of assetsModerate to Severe Plaque Pso

49、riasisUlcerative ColitisRheumatoid ArthritisCrohns DiseasePsoriatic ArthritisSLESjogrens syndromeAlopecia AreataNot exhaustive of assets,programs,or indications1.2023 estimates from Decision Resource Group&BMS Internal Analysis across indications in the U.S.&EU5;SLE:Systemic Lupus Erythematosuscenda

50、kimabLPA1antagonistCD19 NEX TEosinophilic Esophagitis&GastroenteritisIdiopathic&Progressive Pulmonary FibrosisSLEMultiple SclerosisOthersNOT FOR PRODUCT PROMOTIONAL USEHighly Confidential CVS indication-based formulary with 0 step edits Second major PBM secured with one step edit:ESI,30M livesSotykt

51、u is a key growth driver to establish leadership in Immunology20Expansion opportunities across autoimmune2Executing launch in psoriasis and broadening access6 million adults in the U.S.1Focus on growing volume&expanding accessPsoriatic Arthritis:Shared pathogenesis with psoriasis 2024/2025SLE:Substa

52、ntial need for effective oral options 2026Sjogrens syndrome:Shared pathogenesis with SLE with significant unmet need 2027Alopecia Areata3:Significant unmet need in autoimmune hair loss with limited treatment optionsOngoing phase III trials with broad applicability and data anticipated in 2024 20271.

53、Decision Resources Group;BMS Internal Analysis;2.Years indicate expected data readouts;3.Phase 2 POC;SLE:Systemic Lupus ErythematosusNOT FOR PRODUCT PROMOTIONAL USEHighly ConfidentialPotentially differentiated profilePhase 3 registrational trials in IPF&PPF ongoing data expected 2027/28LPA1antagonis

54、t has the potential to be the new standard of care in pulmonary fibrosis21Significant Unmet needProgressive Pulmonary Fibrosis(PPF)140KU.S.prevalence1290KU.S.prevalence1Idiopathic Pulmonary Fibrosis(IPF)IPF is fatal lung disease with 35 year median survival2 Approved therapies have tolerability chal

55、lenges and do not treat underlying fibrosis LPA1antagonist Disease modifying agent andbest-in-class potential60%reduction in lung-function decline3,4 Differentiated tolerability profile1.Decision Resource Group;2.Raghu.Am J Respir Crit Care Med.2011 Mar 15;183(6):788-824.3.Corte TJ,et al.Am J Respir

56、 Crit Care Med.2023;207:A2785.4.Corte TJ,et al.ERS 2023 Presentation#RCT800.NOT FOR PRODUCT PROMOTIONAL USEHighly ConfidentialPotential for massive expansion of cell therapy addressable marketPotential transformative efficacy and safety profile to reset immune systemInitial in-house clinical data fo

57、r lupus expected in 2024|Expanding to Myositis,MS,other diseasesCD19 NEX T:Potential transformative cell therapy for patients with several severe immunologic diseases22Addressable population1 Growing evidence of CAR T-induced immune rest in severe autoimmune diseases,e.g.,Durable remission in SLE CD

58、19 NEX T:Best-in-class Breyanzi construct with improved manufacturing focused on scale and reliabilityHeme malignancyB cell-mediatedAutoimmune5-10 x SLE MS SSc Myositis Other indications1.Decision Resources Group;SLE:Systemic Lupus Erythematosus,SSc:Systemic Sclerosis,MS:Multiple SclerosisNOT FOR PR

59、ODUCT PROMOTIONAL USEHighly ConfidentialRe-establishing Neuroscience across a wide range of conditions with substantial unmet need23Substantial unmet need across millions of patientsNeuroinflammationNeurodegenerationNeuropsychiatry Multiple Sclerosis Alzheimers Disease Parkinsons Disease ALSeIF2b ac

60、tivator Schizophrenia Schizophrenia(adjunctive)Alzheimers disease psychosis Alzheimers disease agitation Bipolar I Mood&anxiety disordersAnti-MTBR-TauFAAH MGLLNot exhaustive of assets,programs,or indications1.Subject to satisfaction of customary closing conditions;anticipated closing for Karuna Ther

61、apeutics in 1H 2024 1CD19 NEX TTYK2i-CNSKarXTNOT FOR PRODUCT PROMOTIONAL USEHighly ConfidentialSchizophrenia approval1.6M2treated patients inthe U.S.KarXT1:Starting next year,opportunity for series of indications supporting continued growth241.Subject to satisfaction of customary closing conditions;

62、anticipated closing 1H 2024 1.Subject to satisfaction of customary closing conditions;anticipated closing 1H 2024 1.Subject to satisfaction of customary closing conditions;anticipated closing 1H 2024 1.Subject to satisfaction of customary closing conditions;anticipated closing 1H 2024.2.DRG Clarivat

63、e,as of July 2023;3.“Alzheimers Disease Association Facts and Figures,”2023202420252026 20282029+Adjunctive schizophreniaPhase 3 dataExpansion within schizophreniaPipeline and future indications Alzheimers Disease Agitation registrational data6M3people living with ADin U.S.Bipolar I Disorderregistra

64、tional dataImpacts 1.4M2patients in U.S.Alzheimers disease psychosis registrational data6M3people living with ADin U.S.Long-acting injectable NOT FOR PRODUCT PROMOTIONAL USEHighly ConfidentialFocus on disciplined executionHow we will deliver251.Build on our leadership in Oncology,Hematology&Cardiova

65、scular2.Continue to grow our presence in Immunology&Neuroscience4.Strategic capital allocation3.Maximize valuefrom our differentiated pipeline&platformsHighly Confidential2022 20232024 20-2030CendakimabIberdomideLPA1antagonistKarXT1MezigdomideCD19 NEX TAlnuctamabGPRC5D CAR TMilvexianB

66、ET inhibitor(986158)GolcadomideAR LDDRYZ1011MYK-224BL-B01D11PRMT5/MTA Inhibitor1Portfolio evolution:Potential to add 16+NMEs over decade26CardiovascularOncologyHematologyImmunologyNew pipeline additions since Jan 2023NMEs by potential year of first approvalPotential for additional 40+LCM opportuniti

67、es across these NMEs&approved products1.Subject to satisfaction of customary closing conditions;anticipated closing of Mirati Therapeutics,Karuna Therapeutics,RayzeBio,&SystImmune in 1H 2024;2.Approved in 2022&expected addition to BMS portfolio in 2024Unmarketed products are subject to positive regi

68、strational trials and regulatory approval1,2Neurosciencerecently approved NOT FOR PRODUCT PROMOTIONAL USEHighly ConfidentialMultiple key pipeline milestones expected in 202427Milestones represent expected data read-outs unless otherwise specified|1.Week 12 primary endpoint data anticipated 2024/2025

69、 2.Subject to satisfaction of customary closing conditions;anticipated closing for Mirati Therapeutics,Karuna Therapeutics,RayzeBio&SystImmune in 1H 2024ABECMA 35L RRMM(KarMMa-3)approvalCendakimab EoE Ph3 PRMT5/MTA Inhibitor2 MTAP-deleted cancers Ph1AR LDD mCRPC Ph1KarXT2 Schizophrenia approvalRYZ10

70、12 ES-SCLC Ph1BL-B01D12(EGFRxHER3 ADC)NSCLC Ph1Krazati(KRASG12CInhibitor)2 1L NSCLC TPS$10B revenue from new product portfolio in 2026 Operating margin target to 37%through 20253$25B NRA for 9 New Product Portfolio in 2030 Primarily annual Total company revenue guidance Total company line-item guida

71、nce Key pipeline events and milestones*See“Forward-Looking Statements and Non-GAAP Financial Information”and“Bristol Myers Squibb Company Reconciliation of Certain GAAP Line Items to Certain Non-GAAP Line Items”1.At constant exchange rates on a risk-adjusted basis 2.Primarily IO&Eliquis;NRA:Non-Risk

72、 Adjusted sales subject to positive registrational trials and health authority approval;Financial projections may contain non promoted sales,BMS promotes only according to label 3.Operating margin 37%through 2025 excludes potential future business developmentKey targets*Return to historical guidance

73、 practiceHighly ConfidentialExecuting on our plan to drive sustainable,top-tier long-term growthRevenue,illustrativeNavigate transition periodMaximize performance through 202535 Drive strong commercial execution Launch new medicines Integrate Mirati,Karuna,RayzeBio1 Ensure on-time delivery of late p

74、ortfolio Deliver against R&D productivity P&L discipline Prosecute early to mid-pipeline Deliver potential from recently acquired assets Continue to enhance pipeline through disciplined BD1.Subject to satisfaction of customary closing conditions;anticipated closing for Mirati Therapeutics,Karuna The

75、rapeutics&RayzeBio in 1H 2024Accelerate growth from late 2020sHighly ConfidentialOur ESG updates and looking ahead 37ESG Materiality Assessment Results2022 ESG Report Completed a global,double ESG materiality assessment1and identified the8 ESG factors that were rated as most“material”by stakeholders

76、 Results showed strong alignment of internal and external stakeholders priorities On August 23,2023,published BMS 2022 ESG Report,2providing increased transparency and disclosures2022 Highlights Include:58%clinical trial sites in diverse metro areas$1B global spend on diverse-owned businesses 8.2%re

77、duction in greenhouse gas emissions across Scopes 1,2,&3 compared to 2021 TOP 8 Material ESG Factors1.Pricing&Patient Access 2.Product Innovation 3.Patient Safety and Product Quality4.Ethics&Conduct 5.Long-Term Value Creation6.Culture and Inclusion&Diversity7.Climate Change&Emissions8.Public Health&

78、Public PolicySocial Capital,36%Human Capital,11%Environment,11%Leadership&Governance,16%Business Model&Innovation,26%Breakdown:Top ESG Issues by ThemeLooking AheadEvolved ESG Strategy based on double materiality assessment will be shared in 2024Task Force on Climate-Related Financial Disclosures(TCF

79、D)report published in December 2023Science-based emissions reduction targets anticipated to be validated by the Science Based Targets Initiative(SBTi)by 2024$150 million to address health disparities will be provided by end of 20251 BMS ESG Materiality Assessment2 BMS 2022 ESG ReportNOT FOR PRODUCT

80、PROMOTIONAL USEHighly ConfidentialYear-Ended December 322Total Revenues$42,518$46,385$46,159Gross Profit$30,745$36,445$36,022Specified items(a)$3,300$603$356Gross Profit excluding specified items$34,045$37,048$36,378Marketing,Selling and Administrative$7,661$7,690$7,814Specified items(a)(

81、$279)($3)($79)Marketing,Selling and Administrative excluding specified items$7,382$7,687$7,735Research and Development$10,048$10,195$9,509Specified items(a)($903)($843)($308)Research and Development excluding specified items$9,145$9,352$9,201Operating margin31%40%41%Specified items(a)10%3%1%Operatin

82、g margin excluding specified items(b)41%43%42%Bristol Myers Squibb Company Reconciliation of Certain GAAP Line Items to Certain Non-GAAP Line Items38(a):An explanation of these non-GAAP financial measures and a reconciliation to the most directly comparable GAAP financial measure are available on ou

83、r website at margin on Specified Items represents the difference between the GAAP and Non-GAAP operating margin(Unaudited,dollars in millions)Highly ConfidentialPhase IIPhase IClinical Development Portfolio Phase I and II 39 Anti-CTLA-4 NF Probody TherapeuticSolid TumorsLung CancerColorectal Cancer

84、Anti-Fucosyl GM1RR Small Cell Lung Cancer Anti-IL-8Solid Tumors Anti-NKG2ANon-Small Cell Lung Cancer BET Inhibitor(BMS-986378)Solid Tumors farletuzumab ecteribulinOvarian CancerNon-Small Cell Lung Cancernivolumab+relatlimabStage IV 1L Non-Small Cell Lung Cancer1L Hepatocellular CarcinomaAUGTYRONTRK

85、Pan-Tumor BET Inhibitor(BMS-986158)1L MyelofibrosisBREYANZIRR Follicular Lymphoma(FL)RR Marginal Zone Lymphoma(MZL)RR Mantle Cell Lymphoma(MCL)golcadomideRR Non-Hodgkins LymphomaONUREGMyelodysplastic Syndrome REBLOZYLA-ThalassemiaCAMZYOSHeart Failure with preserved Ejection Fraction(HFpEF)danicamtiv

86、Dilated Cardiomyopathy MYK-224Obstructive Hypertrophic CardiomyopathyHeart Failure with preserved Ejection Fraction(HFpEF)afimetoranSystemic Lupus ErythematosusSOTYKTUAlopecia AreataDiscoid Lupus Erythematosus TYK2 Inhibitor(BMS-986322)Moderate-to-Severe Psoriasis AHR Antagonist*Solid Tumors Anti-CC

87、R8Solid Tumors Anti-ILT4Solid Tumors AR LDD1L,2L Metastatic Castration-Resistant Prostate Cancer DGK InhibitorSolid Tumors Helios CELMoDSolid Tumors JNK InhibitorSolid Tumors MAGE A4/8 TCER*Solid Tumors NME 1Prostate Cancer SHP2 InhibitorSolid Tumors TGF InhibitorSolid Tumors TIGIT BispecificSolid T

88、umorsLung CancerGastric Cancer alnuctamabRR Multiple Myeloma Anti-SIRPHematologic Malignancies BCL6 LDDLymphoma BCMA NKERR Multiple Myeloma BET Inhibitor(BMS-986378)RR Non-Hodgkins Lymphoma CD33-GSPT1 ADCAcute Myeloid Leukemia CD33 NKEAcute Myeloid Leukemia CK1 DegraderHematologic Malignancies Dual

89、Targeting BCMAxGPRC5D CAR TRR Multiple Myelomagolcadomide1L Diffuse Large B-cell Lymphoma GPRC5D CAR TRR Multiple Myeloma FXIa InhibitorThrombotic Disorders Anti-CD40Autoimmune Disease CD19 NEX TSevere Refractory Systemic Lupus Erythematosus IL2-CD25Autoimmune Disease NME 2Autoimmune Disease PKC Inh

90、ibitorAutoimmune Disease Anti-MTBR-TauAlzheimers Disease eIF2b ActivatorNeuroscience FAAH/MGLL Dual InhibitorNeuroscience TYK2 Inhibitor(BMS-986465)Neuroinflammation diseasesHematologyNeuroscienceOncologyImmunologyCV*Partner-run studyNME leading indication Trials exploring various combinationsData a

91、s of December 31,2023Highly ConfidentialPhase IIIClinical Development Portfolio Phase III Registration US,EU,JPOPDIVOAdjuvant Hepatocellular CarcinomaPeri-adjuvant Muscle-Invasive Urothelial CarcinomaPeri-adjuvant Non-Small Cell Lung CancerStage IB-IIIA Adjuvant NSCLC*OPDIVO+YERVOY1L Hepatocellular

92、Carcinoma1L Muscle Invasive Urothelial Carcinoma1L+Microsatellite Instability High Colorectal CancerStage 3 Unresectable Non-Small Cell Lung CancerOPDUALAGAdjuvant Melanoma SC nivolumab+relatlimab+rHuPH201L Melanoma SC nivolumab+rHuPH20(multi-indications)2L Renal Cell Carcinoma ABECMANewly Diagnosed

93、 Multiple Myeloma with Suboptimal Response post-ASCTiberdomide2L+Multiple MyelomaPost-Autologous Stem Cell Therapy Maintenance Newly Diagnosed Multiple Myelomamezigdomide2L+Multiple Myeloma Vd2L+Multiple Myeloma KdREBLOZYL1L TD Myelofibrosis Associated Anemia1L NTD Myelodysplastic Syndrome Associate

94、d AnemiaCAMZYOSNon-Obstructive Hypertrophic CardiomyopathymilvexianSecondary Stroke Prevention*Acute Coronary Syndrome*Atrial Fibrillation*cendakimabEosinophilic EsophagitisEosinophilic Gastroenteritis#LPA1 AntagonistIdiopathic Pulmonary Fibrosis(IPF)Progressive Pulmonary Fibrosis(PPF)obexelimab*IgG

95、4-Related DiseaseSOTYKTUPsoriatic ArthritisSystemic Lupus ErythematosusSjgrens SyndromeZEPOSIACrohns DiseaseAUGTYROROS1 NSCLC(EU,JP)NTRK Pan-Tumor(EU)OPDIVO+YERVOY1L Muscle Invasive Urothelial Carcinoma(US,EU,JP)ABECMA3-5L Multiple Myeloma(US,EU)BREYANZI3L+Chronic Lymphocytic Leukemia(US)RR Follicul

96、ar Lymphoma(JP)REBLOZYL1L TD Myelodysplastic Syndrome Associated Anemia(EU,JP)Development Partnerships:ABECMA:2seventy bio;AHR:Ikena Oncology;farletuzumab ecteribulin:Eisai;rHuPH20:Halozyme;MAGEA4/8 TCER:Immatics;milvexian:J&J Innovative Medicine;OPDIVO,YERVOY,OPDUALAG in Japan:Ono;PKC Inhibitor:Exscientia;REBLOZYL:Merck;SHP2 Inhibitor:BridgeBio Pharma;TIGIT Bispecific:Agenus;obexelimab:Zenas BioPharma in Japan,South Korea,Taiwan,HK,Singapore,and Australia40Data as of December 31,2023HematologyNeuroscienceOncologyImmunologyCV*#Partner-run studyNME leading indicationJapan only